Table 3.
Prevalence of antibiotic resistant pathogens according to the antibiotic of interest
| COVID-19 | Non COVID-19 | p value | OR | 95% CI | |
|---|---|---|---|---|---|
| Pseudomonas spp. MDR, N (%) | 42 (36.8) | 14 (35) | 0.83 | 1.08 | 0.51–2.3 |
| Pseudomonas spp. PIP/TZ-R, N (%) | 75 (65.8) | 15 (37.5) | 0.001 | 3.21 | 1.52–6.77 |
| Pseudomonas spp. CARBA-R, N (%) | 60 (52.6) | 10 (25) | 0.005 | 3.33 | 1.49–7.45 |
| Pseudomonas spp. CTZ/CEF-R, N (%) | 40 (35.1) | 14 (35) | 0.86 | 1 | 0.47–2.14 |
| Enterobacterales MDR, N (%) | 33 (32.7) | 34 (33.3) | 0.96 | 0.97 | 0.54–1.74 |
| Enterobacterales PIP/TZ-R, N (%) | 33 (327) | 18 (17.6) | 0.02 | 2.27 | 1.17–4.37 |
| Enterobacterales CARBA-R, N (%) | 0 (0) | 0 (0) | – | – | – |
| Enterobacterales 3GC-R. N (%) | 16 (15.8) | 18 (17.6) | 0.1 | 1.19 | 0.6–2.36 |
Differences statistically significant are given in bold
MDR multi drug resistant, PIP/TZ-R/S piperacillin/tazobactam resistant/susceptible, CARBA-R/S carbapenem resistant/susceptible, CTZ/CEF-R/S ceftazidime/cefepime resistant/susceptible